Participants 34 65 4
patients with advanced melanoma
Participants 325 375 5
previously treated patients with advanced melanoma
Participants 470 517 3
enrolled patients without regard to HLA subtype
Participants 580 616 5
class-I HLA-A*0201-positive patients
Participants 752 808 4
phase II trials and was available for 93.5% of patients.
Participants 932 999 4
pretreated patients randomized to 0.3, 3, or 10 mg/kg ipilimumab in
Participants 1330 1362 3
137 HLA-A*0201-positive patients
